Gold prices fall as geopolitical tensions ease; U.S. CPI looms
Investing.com - Brookline Capital Markets initiated coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and a price target of $18.00 on Monday. The clinical-stage company, currently trading at $4.43 with a market cap of $33.83M, has analyst targets ranging from $12.24 to $30.46.
The clinical-stage pharmaceutical company is developing a pipeline of radiopharmaceutical candidates, with seven programs primarily in preclinical or Phase 1 stages, according to Brookline Capital.
RAD101, the company’s most advanced candidate, is a novel imaging agent for brain metastases currently in Phase 2b trials, with data from the first two cohorts expected in the third quarter of 2025.
Brookline Capital noted that several additional studies should produce early readouts in the second half of 2025, and the company has sufficient cash to fund operations until June 2026.
Buy-rated Lantheus (NASDAQ:LNTH) Holdings owns 12% of Radiopharm Theranostics stock, providing financial and other support, which Brookline Capital suggests presents potential for an acquisition in the future. Get deeper insights into RADX’s financial health and 7 additional key ProTips with InvestingPro.
In other recent news, Radiopharm Theranostics announced it has received a $4.5 million research and development tax incentive from Australia’s R&D Tax Incentive program. This financial support is intended for companies conducting eligible research and development activities in Australia. Additionally, ThinkEquity has initiated coverage on Radiopharm Theranostics with a Buy rating and a price target of $15, reflecting confidence in the company’s growth potential. The firm highlights Radiopharm’s diversified pipeline and strategic positioning in the radiopharmaceutical industry. Furthermore, Radiopharm has started a Phase IIb trial for a novel brain cancer imaging agent, marking a significant step in advancing diagnostic tools for oncology. The trial aims to evaluate the efficacy of new imaging technology for brain metastases, with the first patient already dosed. This development could lead to improvements in diagnosing and managing metastatic brain tumors. Radiopharm emphasized that this information should not be considered filed for purposes of the Exchange Act.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.